Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial crawled time : 16:00 save search
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients
Published: 2024-04-09 (Crawled : 16:00) - globenewswire.com
RAPT | $7.9 -1.25% -1.2% 240K
|
Health Technology
|
| O: 0.0%
H: 3.37%
C: 1.44%
cancer immunotherapy trial therapeutics results
Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen
Published: 2024-04-09 (Crawled : 16:00) - globenewswire.com
ATOS | $1.5 0.67% 1.0% 1.8M
|
Health Technology
|
| O: 0.57%
H: 11.65%
C: 4.55%
disease control treatment trial therapeutics
Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial
Published: 2024-04-02 (Crawled : 16:00) - biospace.com/
KRBP | $2.71 2.65% -90.21% 0
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -5.0%
favorable biopharma trial
Kiora Pharmaceuticals to Present Additional Data from Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting
Published: 2024-03-28 (Crawled : 16:00) - biospace.com/
KPRX | $0.5058 -12.72% -14.98% 100
|
Manufacturing
|
| O: -2.26%
H: 20.0%
C: 17.67%
pharmaceuticals meeting trial
Clinical Trial Supply & Logistics Market Projected to Reach $41.04 billion by 2030 - Exclusive Report by 360iResearch
Published: 2024-03-25 (Crawled : 16:00) - prnewswire.com
TMO | News | $577.39 0.49% -0.38% 1.7M
|
Health Technology
|
| O: 0.02%
H: 0.31%
C: -1.65%
INFY | $17.04 -0.7% 0.76% 36K
|
Technology Services
|
| O: 0.4%
H: 0.0%
C: -0.9%
CTLT | $55.95 -0.14% -0.18% 1.6M
|
Health Technology
|
| O: 0.54%
H: 0.82%
C: 0.55%
ICLR | News | $309.44 0.98% 0.76% 8
|
Health Technology
|
| O: 0.02%
H: 0.34%
C: -0.68%
report reach trial market
FDA Rejects Regeneron’s Blood Cancer Therapy for Two Forms of Lymphoma
Published: 2024-03-25 (Crawled : 16:00) - biospace.com/
SNYNF | News | $94.0 -0.27% -2.18% 0
|
Health Technology
|
| O: -100.0%
H: NaN%
C: Infinity%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: 0.42%
H: 0.0%
C: 0.0%
fda cancer blood therapy
Sonnet BioTherapeutics Announces Early Safety Data from the Company’s Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study’s Initial Pre-Specified Objective
Published: 2024-03-11 (Crawled : 16:00) - biospace.com/
SONN | $1.845 3.65% 5.83% 6.2K
|
Health Technology
|
| O: 10.81%
H: 7.8%
C: 0.98%
son-080 trial
Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024
Published: 2024-02-29 (Crawled : 16:00) - biospace.com/
IMUX | $1.24 0.0% 90
|
Health Technology
|
| O: 0.71%
H: 4.26%
C: 3.9%
trials
Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial
Published: 2024-02-26 (Crawled : 16:00) - biospace.com/
ATNM | $7.06 1.44% 2.83% 28
|
Health Technology
|
| O: 2.04%
H: 19.98%
C: 18.71%
active aml trial
Skye Bioscience Receives IND Clearance for Phase 2 Clinical Trial of Nimacimab in Obesity and Chronic Kidney Disease
Published: 2024-01-09 (Crawled : 16:00) - biospace.com/
SKYE | $12.85 -8.41% -9.23% 110K
|
Transportation and Warehousing
|
| O: -7.02%
H: 29.11%
C: 15.56%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: 0.0%
obesity disease kidney bioscience clearance trial
Shattuck Labs Announces Positive Initial Topline Data from Ongoing Phase 1 A/B Dose Expansion Clinical Trial of SL-172154
Published: 2023-12-13 (Crawled : 16:00) - biospace.com/
STTK | $9.9 4.32% 3.85% 230K
|
Health Technology
|
| O: 107.58%
H: 23.74%
C: 10.96%
sl-1721 positive ongoing expansion topline trial
Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
Published: 2023-12-13 (Crawled : 16:00) - biospace.com/
VSTM | $9.31 -3.12% -3.44% 79K
|
Health Technology
|
| O: -0.14%
H: 10.83%
C: 10.83%
avutometinib cancer defactinib trial
J&J, Genmab Unveil Darzalex Faspro Data with Eye Toward Earlier Multiple Myel...
Published: 2023-12-13 (Crawled : 16:00) - biospace.com/
JNJ | News | $148.53 -0.69% 0.11% 67K
|
Health Technology
|
| O: -0.71%
H: 0.0%
C: 0.0%
darzalex eye faspro
Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissions - December 8, 2023
Published: 2023-12-08 (Crawled : 16:00) - biospace.com/
NVSEF | News | $96.0 0.94% 6.88% 0
|
Health Technology
|
| O: -1.29%
H: 0.4%
C: 0.4%
PFE | News 4 | $26.27 -0.19% -0.38% 130K
|
Health Technology
|
| O: 0.07%
H: 1.1%
C: 0.45%
NVS | News | $98.35 1.1% 0.32% 5.9K
|
Health Technology
|
| O: 0.19%
H: 0.35%
C: 0.2%
kisqali breast risk novartis
Coherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI™ (toripalimab-tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Association
Published: 2023-11-28 (Crawled : 16:00) - globenewswire.com
CHRS | $2.02 -7.34% -7.39% 2.6K
|
Health Technology
|
| O: -1.55%
H: 12.83%
C: 10.47%
piter-02 association positive publication treatment medical trial results
Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
Published: 2023-11-03 (Crawled : 16:00) - globenewswire.com
CADL | $6.05 2.37% 1.99% 3.5K
|
|
| O: 4.63%
H: 2.0%
C: -24.97%
can-2409 positive cancer pancreatic trial therapeutics
Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms’ Tumor 1 Positive Cancers at SITC 2023
Published: 2023-11-03 (Crawled : 16:00) - globenewswire.com
CUE | $1.42 -5.33% -4.9% 1.5K
|
Health Technology
|
| O: 1.35%
H: 16.44%
C: 8.89%
cue-101 positive cue cancer biopharma tumor cue-102 trials
RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC
Published: 2023-11-03 (Crawled : 16:00) - globenewswire.com
RAPT | $7.9 -1.25% -1.2% 240K
|
Health Technology
|
| O: 1.97%
H: 12.63%
C: 6.97%
flx475 positive trial therapeutics response
Molecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting
Published: 2023-11-03 (Crawled : 16:00) - globenewswire.com
MOLN | $3.61 -6.23% -3.54% 0
|
Professional, Scientific, and T...
|
| O: 0.72%
H: 9.74%
C: 9.74%
mp0317 tumors positive ongoing meeting trial molecular
Skye Bioscience Announces Positive Phase 1 Trial Results for SBI-100 Ophthalmic Emulsion, Its First-in-Class CB1 Agonist Being Developed for the Treatment of Glaucoma
Published: 2023-10-25 (Crawled : 14:00) - biospace.com/
SKYE | $12.85 -8.41% -9.23% 110K
|
Transportation and Warehousing
|
| O: -0.31%
H: 0.0%
C: -23.0%
sbi-100 glaucoma agonist positive bioscience treatment trial results ophthalmic
Gainers vs Losers
| 60% | 40% |
Top 10 Gainers
BOF | $2.08 77.78% 39.06% 110M
|
OPTN | $0.9253 -4.38% 30.38% 5.3M
|
Health Services
PCSA | $1.62 1.25% 21.95% 7.1M
|
Producer Manufacturing
BHIL | $0.1793 -4.37% 19.24% 340K
|
Agriculture, Forestry, Fishing ...
UMAC | $1.48 -1.33% 14.87% 20K
|
CI | $352.28 -0.11% 13.53% 2
|
Health Services
CIG.C | $2.89 -1.37% 12.8% 2.3K
|
n/a
BMTX 4 | $1.545 0.98% 10.03% 2.5K
|
Information
OMQS | $0.411 -2.81% 9.83% 1.2M
|
Professional, Scientific, and T...
TAL | $12.26 0.57% 9.22% 12M
|
Consumer Services
Your saved searches
Save your searches and get alerts when important news are released.